Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Auxora

Other · developed by CalciMedica

Phase 2 Most advanced trial (none active)

CALC Developer

1 Registered trials

What is Auxora?

Auxora is a drug containing zegocractin, dosed intravenously over 4 hours in a multi-dose regimen. It is studied in acute kidney injury.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Renal & urology
Developer: CalciMedica, Inc. (CALC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06374797	Phase 2	Acute Kidney Injury	Terminated	CALC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Kidney Injury

Sources

ClinicalTrials.gov NCT06374797

Updated Oct 11, 2026. Something wrong or missing? Report it on the CALC page.

Follow CALC, the company behind Auxora

See CALC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CALC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z